Chinese guideline for clinical application of sirolimus in liver transplant recipients with hepatocellular carcinoma (2024 edition)

doi:10.3877/cma.j.issn.1674-3903.2024.06.006

Abstract

Abstract:

Sirolimus is a mammalian target of rapamycin inhibitor.Sirolimus is a frequently utilized immunosuppressant for liver transplant recipients, serving to both prevent rejection and inhibit tumor cell growth.In order to further standardize and optimize the application of sirolimus in liver transplant recipients for hepatocellular carcinoma in China, the Liver Transplantation Group,Branch of Organ Transplantation of Chinese Medical Association organized domestic experts to formulate the Chinese guideline for clinical application of sirolimus in liver transplant recipients with hepatocellular carcinoma (2024 edition) based on the Chinese expert consensus on application of sirolimus in liver transplantation for hepatocellular carcinoma (2020 edition), and fully drawing on relevant domestic and foreign literature and combining evidence-based medicine and China′s clinical practice experience,focusing on the clinical effects, application schemes, adverse reactions and drug monitoring principles of sirolimus in liver transplant recipients for hepatocellular carcinoma.

Key words: Liver transplantation, Hepatocellular carcinoma, Sirolimus

Transplantation Group, Branch of Organ Transplantation of Chinese Liver. Chinese guideline for clinical application of sirolimus in liver transplant recipients with hepatocellular carcinoma (2024 edition)[J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(06): 374-385.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2024.06.006

https://zhyzzz.cma-cmc.com.cn/EN/Y2024/V18/I06/374

Figures/Tables 2

References 120

1	Han B, Zheng R, Zeng H, et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
2	Ling S, Jiang G, Que Q, et al.Liver transplantation in patients with liver failure: twenty years of experience from China[J].Liver Int,2022,42(9):2110-2116.
3	中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组.中国肝癌肝移植临床实践指南(2021 版)[J/CD].中华移植杂志:电子版,2021,15(6):321-328.
4	中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2024 年版)[J].协和医学杂志,2024,15(3):532-559.
5	Kwong AJ, Kim WR, Lake JR, et al.OPTN/SRTR 2022 annual data report: liver[J].Am J Transplant, 2024, 24(2S1): S176-S265.
6	Chen J, Shen T, Li J, et al.Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition)[J].Chin Med J (Engl),2022,135(24):2911-2913.
7	Sapisochin G, Bruix J.Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J].Nat Rev Gastroenterol Hepatol,2017,14(4):203-217.
8	Xu X, Lu D, Ling Q, et al.Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J].Gut,2016,65(6): 1035-1041.
9	谢琴芬, 郑树森.肝癌患者肝移植后的免疫抑制剂应用[J].中华器官移植杂志,2013,34(9):573-575.
10	Rodriguez-peralvarez M, Tsochatzis E, Naveas MC, et al.Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J].J Hepatol,2013,59(6):1193-1199.
11	Vivarelli M, Cucchetti A, La Barba G, et al.Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors:reassessment of risk factors for tumor recurrence[J].Ann Surg,2008,248(5):857-862.
12	Vivarelli M, Cucchetti A, Piscaglia F, et al.Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma:key role of immunosuppression[J].Liver Transpl,2005,11(5):497-503.
13	Fan GH, Zhang CZ, Gao FQ, et al.A mixed blessing for liver transplantation patients -Rapamycin[J].Hepatobiliary Pancreat Dis Int,2023,22(1):14-21.
14	Kim WR, Lake JR,Smith JM,et al.OPTN/SRTR 2016 annual data report: liver[J].Am J Transplant, 2018, 18(Suppl 1): S172-S253.
15	Shenoy S, Hardinger KL, Crippin J, et al.Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective,randomized, single-center trial [J].Transplantation, 2007, 83(10):1389-1392.
16	Harper SJ, Gelson W, Harper IG, et al.Switching to sirolimusbased immune suppression after liver transplantation is safe and effective: a single-center experience[J].Transplantation, 2011, 91(1):128-132.
17	Buchholz BM, Ferguson JW, Schnitzbauer AA, et al.Randomized sirolimus-based early calcineurin inhibitor reduction in liver transplantation:impact on renal function[J].Transplantation,2020,104(5):1003-1018.
18	Kim DS, Yoon YI, Kim BK, et al.Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation[J].Hepatol Int,2024,18(2):299-383.
19	Andrews JC, Schunemann HJ, Oxman AD, et al.GRADE guidelines:15.Going from evidence to recommendation-determinants of a recommendation′s direction and strength[J].J Clin Epidemiol,2013,66(7):726-735.
20	Guyatt G, Oxman AD, Akl EA, et al.GRADE guidelines: 1.Introduction-GRADE evidence profiles and summary of findings tables[J].J Clin Epidemiol,2011,64(4):383-394.
21	中国医师协会器官移植医师分会肝移植学组, 中华医学会器官移植学分会肝移植学组.西罗莫司在肝癌肝移植中应用的中国专家共识(2020 版)[J].中华消化外科杂志,2020,19(6):589-597.
22	Bob P, Chris B, Dave S, et al.Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009)[EB/OL].[2024-12-13].https:/ /www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidencemarch-2009.
23	Halloran PF.Immunosuppressive drugs for kidney transplantation[J].N Engl J Med,2004,351(26):2715-2729.
24	Watson CJ, Friend PJ, Jamieson NV, et al.Sirolimus: a potent new immunosuppressant for liver transplantation[J].Transplantation,1999,67(4):505-509.
25	Mchenry CR, Rosen IB, Walfish PG, et al.Oral calcium load test:diagnostic and physiologic implications in hyperparathyroidism[J].Surgery,1990,108(6):1026-1031; discussion 1032.
26	Mcalister VC, Peltekian KM, Malatjalian DA, et al.Orthotopic liver transplantation using low-dose tacrolimus and sirolimus[J].Liver Transpl,2001,7(8):701-708.
27	Dunkelberg JC, Trotter JF, Wachs M, et al.Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications[J].Liver Transpl, 2003, 9(5):463-468.
28	Zhou J, Fan J, Wang Z, et al.Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience[J].World J Gastroenterol,2006,12(19):3114-3118.
29	Mckenna GJ, Trotter JF.Sirolimus--it doesn′t deserve its bad Rap(a)[J].J Hepatol,2012,56(1):285-287.
30	Geissler EK, Schnitzbauer AA,Zulke C,et al.Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized,multicenter, open-label phase 3 trial[J].Transplantation, 2016,100(1):116-125.
31	Schnitzbauer AA, Zuelke C, Graeb C, et al.A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma[J].BMC Cancer,2010,10:190.
32	Zaghla H, Selby RR, Chan LS, et al.A comparison of sirolimus vs.calcineurin inhibitor-based immunosuppressive therapies in liver transplantation[J].Aliment Pharmacol Ther, 2006, 23(4): 513-520.
33	Saner FH, Cicinnati VR, Sotiropoulos G, et al.Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation[J].Liver Int,2012,32(2):179-188.
34	中华医学会器官移植学分会,中国医师协会器官移植医师分会,等.中国肝移植受者肾损伤管理临床实践指南(2023 版)[J/CD].中华移植杂志:电子版,2023,17(6):321-331.
35	Cotterell AH, Fisher RA, King AL, et al.Calcineurin inhibitorinduced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent[J].Clin Transplant,2002,16(Suppl 7): S49-S51.
36	Teperman L, Moonka D, Sebastian A, et al.Calcineurin inhibitorfree mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial[J].Liver Transpl,2013,19(7):675-689.
37	Ju WQ, Guo ZY, Liang WH, et al.Sirolimus conversion in liver transplantrecipientswithcalcineurininhibitor-induced complications: efficacy and safety[J].Exp Clin Transplant, 2012,10(2):132-135.
38	Yang YJ, Chen DZ, Li LX, et al.Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency[J].Transplant Proc,2008,40(5):1541-1544.
39	Campbell MS, Rai J, Kozin E, et al.Effects of sirolimus vs.calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation[J].Clin Transplant,2007,21(3):377-384.
40	Perrakis A, Schwarz K, Yedibela S, et al.Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications,safety, and outcome[J].Transplant Proc, 2011, 43(10): 3702-3707.
41	Tsai KF, Li LC, Hsu CN, et al.Effects of conversion from calcineurin inhibitors to sirolimus or everolimus on renal function and possible mechanisms in liver transplant recipients [ J].J Clin Pharmacol,2019,59(3):326-334.
42	Kawahara T, Asthana S, Kneteman NM.m-TOR inhibitors: what role in liver transplantation?[J].J Hepatol, 2011, 55(6): 1441-1451.
43	Sahin F, Kannangai R, Adegbola O, et al.mTOR and P70 S6 kinase expression in primary liver neoplasms[J].Clin Cancer Res,2004,10(24):8421-8425.
44	Lu EW, Deftos M,Tighe H,et al.Generation and characterization of two monoclonal self-associating IgG rheumatoid factors from a rheumatoid synovium[J].Arthritis Rheum, 1992, 35(1): 101-105.
45	Semela D, Piguet AC, Kolev M, et al.Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma[J].J Hepatol,2007,46(5):840-848.
46	Guba M, Yezhelyev M, Eichhorn ME, et al.Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF[J].Blood,2005,105(11):4463-4469.
47	Guba M, Graeb C, Jauch KW, et al.Pro-and anti-cancer effects of immunosuppressive agents used in organ transplantation [ J].Transplantation,2004,77(12):1777-1782.
48	Lee KW, Kim SH, Yoon KC, et al.Sirolimus prolongs survival after living donor liver transplantation for hepatocellular carcinoma beyond milan criteria: a prospective, randomised, open-label, multicentre phase 2 trial[J].J Clin Med,2020,9(10):3264.
49	Menon KV, Hakeem AR, Heaton ND.Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J].Aliment Pharmacol Ther, 2013, 37(4):411-419.
50	Yanik EL, Chinnakotla S, Gustafson SK, et al.Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J].Liver Transpl,2016,22(5):627-634.
51	Tejedor-Tejada J, Alonso-Martín C, Almohalla-Álvarez C, et al.Immunosuppressive treatment with mTOR inhibitors for malignancies after liver transplantation: long-term survival retrospective analysis[J].Transplant Proc,2020,52(5):1507-1510.
52	Zhang G, Duan B, Li G.mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: a systematic review and meta-analysis[J].Clin Transplant, 2022, 36(12): e14823.
53	Yan X, Huang S, Yang Y, et al.Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis[J].Liver Transpl, 2022, 28(6):1063-1077.
54	De Visser KE, Joyce JA.The evolving tumor microenvironment:From cancer initiation to metastatic outgrowth[J].Cancer Cell,2023,41(3):374-403.
55	张琳成, 詹启帆, 赵禹迪,等.肝癌肝移植术后免疫抑制方案的网状荟萃分析[J/CD].中华移植杂志:电子版, 2023, 17(6):362-371.
56	Zhou J, Wang Z,Wu ZQ,et al.Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria[J].Transplant Proc, 2008,40(10):3548-3553.
57	Ling S, Feng T, Zhan Q, et al.Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria[J].Ann Transl Med,2020,8(4):80.
58	Su RY, Ling SB, Shan QN, et al.Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: a single-arm, multicenter, prospective study[J].Hepatobiliary Pancreat Dis Int,2022,21(2):106-112.
59	倪彦彬, 栗光明, 王福顺, 等.单中心肝细胞癌患者肝移植术后长期生存情况分析[J].中华普通外科杂志, 2023, 38(9): 641-647.
60	Xu SL, Zhang YC, Wang GY, et al.Survival analysis of sirolimusbased immunosuppression in liver transplantation in patients with hepatocellular carcinoma [J].Clin Res Hepatol Gastroenterol,2016,40(6):674-681.
61	Ling S, Zhan Q, Jiang G, et al.E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation[J].Am J Transplant,2022,22(10):2323-2336.
62	Zhang L, Zhou W, Zheng S, et al.An E2F7/TSC1-based model for predicting the efficacy of sirolimus after liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J].Chin Med J(Engl),2024,137(16):1973-1975.
63	Perl A.mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging[J].Ann N Y Acad Sci,2015,1346(1):33-44.
64	Houde VP, Brule S, Festuccia WT, et al.Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue[J].Diabetes,2010,59(6):1338-1348.
65	Chang JW, Yang HH, Lin NC, et al.Risk factors for fractures following liver transplantation: a population-based cohort study[J].Ann Med,2023,55(1):2230871.
66	Zhang L, Liu P, Zhuang L, et al.mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma[J].Mol Biomed,2024,5(1):9.
67	Hu AB, Wu LW, Tai Q, et al.Safety and efficacy of four steroidminimization protocols in liver transplant recipients:3-year follow-up in a single center[J].J Dig Dis,2013,14(1):38-44.
68	Toso C, Merani S, Bigam DL, et al.Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma[J].Hepatology, 2010,51(4):1237-1243.
69	Liang W, Wang D, Ling X, et al.Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis[J].Liver Transpl, 2012, 18(1): 62-69.
70	Zhang ZH, Li LX, Li P, et al.Sirolimus in liver transplant recipients with hepatocellular carcinoma: an updated meta-analysis[J].J Invest Surg,2019,32(7):632-641.
71	Alamo JM, Bernal C, Marin LM, et al.Antitumor efficacy of mammalian target of rapamycin inhibitor therapy in liver transplant recipients with oncological disease: a case-control study [ J].Transplant Proc,2012,44(7):2089-2092.
72	Chinnakotla S, Davis GL,Vasani S,et al.Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation[J].Liver Transpl,2009,15(12):1834-1842.
73	Zimmerman MA, Trotter JF, Wachs M, et al.Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J].Liver Transpl,2008,14(5):633-638.
74	Schnitzbauer AA, Filmann N, Adam R, et al.mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors[J].Ann Surg, 2020, 272(5): 855-862.
75	Abdelmalek MF, Humar A, Stickel F, et al.Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial[J].Am J Transplant,2012, 12(3):694-705.
76	Asrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial[J].Am J Transplant,2014,14(2):356-366.
77	Mulder MB, Van Hoek B, Van Den Berg AP, et al.Three-year results of renal function in liver transplant recipients on low-dose sirolimus and tacrolimus: a multicenter, randomized, controlled trial[J].Liver Transpl,2023,29(2):184-195.
78	Schnitzbauer AA, Sothmann J, Baier L, et al.Calcineurin inhibitor free de novo immunosuppression in liver transplant recipients with pretransplant renal impairment:results of a pilot study (PATRON07)[J].Transplantation,2015,99(12):2565-2575.
79	Wang Z, Zhou J, Fan J, et al.Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma[J].Clin Cancer Res, 2008, 14(16):5124-5130.
80	Ji S, Feng L, Fu Z, et al.Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology[J].Sci Transl Med,2023,15(706): eadg3358.
81	Yu J, Ling S, Hong J, et al.TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma[J].J Immunother Cancer,2023,11(11): e007479.
82	Bang K, Casadei-gardini A, Yoo C, et al.Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation[J].Cancer Med,2023,12(3):2572-2579.
83	Kudo M, Finn RS, Qin S, et al.Lenvatinib versus sorafenib in firstline treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J].Lancet, 2018, 391(10126):1163-1173.
84	Invernizzi F, Iavarone M, Zavaglia C, et al.Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation[J].Transplantation, 2020, 104(3):568-574.
85	Abdelmalek MF, Humar A, Stickel F, et al.Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial[J].Am J Transplant,2012, 12(3):694-705.
86	Charlton M, Levitsky J, Aqel B, et al.International liver transplantation society consensus statement on immunosuppression in liver transplant recipients[J].Transplantation,2018,102(5):727-743.
87	Colmenero J, Tabrizian P, Bhangui P, et al. De novo malignancy after liver transplantation: risk assessment, prevention, and management-guidelines from the ILTS-SETH consensus conference[J].Transplantation,2022,106(1): e30-e45.
88	Garbe C, Amaral T, Peris K, et al.European consensus-based interdisciplinary guideline for melanoma.Part 2: treatment -update 2022[J].Eur J Cancer,2022,170:256-284.
89	Stallone G, Schena A, Infante B, et al.Sirolimus for Kaposi′s sarcoma in renal-transplant recipients[J].N Engl J Med,2005,352(13):1317-1323.
90	Mumtaz K, Faisal N, Marquez M, et al.Post-transplant lymphoproliferative disorder in liver recipients: Characteristics,management, and outcome from a single-centre experience with >1 000 liver transplantations[J].Can J Gastroenterol Hepatol,2015,29(8):417-422.
91	Thimonier E, Guillaud O, Walter T, et al.Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease[J].Clin Transplant,2014,28(12):1339-1348.
92	Vivarelli M, Dazzi A, Zanello M, et al.Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma[J].Transplantation,2010,89(2):227-231.
93	US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.Common terminology criteria for adverse events (CTCAE) version 5 [EB/OL].(2017-11-27)[2024-12-13 ].https:/ /ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
94	危荣沥, 徐骁.肝细胞癌肝移植分子分型与精准治疗[J/CD].实用器官移植电子杂志,2019,7(1):62.
95	Kaplan B, Qazi Y, Wellen JR.Strategies for the management of adverse events associated with mTOR inhibitors[J].Transplant Rev(Orlando),2014,28(3):126-133.
96	Silva AC, Nogueira P, Machado MV.Hepatic steatosis after liver transplantation: a systematic review and meta-analysis[J].Liver Transpl,2023,29(4):431-448.
97	Fan G, Zhang C, Wei X, et al.NEAT1/hsa-miR-372-3p axis participates in rapamycin-induced lipid metabolic disorder[J].Free Radic Biol Med,2021,167:1-11.
98	Busaidy NL, Farooki A, Dowlati A, et al.Management of metabolic effects associated with anticancer agents targeting the PI3K-AktmTOR pathway[J].J Clin Oncol,2012,30(23):2919-2928.
99	Nguyen LS, Vautier M, Allenbach Y, et al.Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation[J].Drug Saf,2019,42(7):813-825.
100	蔡涛, 曹经琳, 窦剑, 等.肝移植术后血小板减少的诊断与治疗同步[J].器官移植,2024,15(6):964-969.
101	Sofroniadou S, Kassimatis T, Goldsmith D.Anaemia, microcytosis and sirolimus--is iron the missing link? [ J].Nephrol Dial Transplant,2010,25(5):1667-1675.
102	Mcdonald MA, Gustafsson F, Almasood A, et al.Sirolimus is associated with impaired hematopoiesis in heart transplant patients?A retrospective analysis[J].Transplant Proc,2010,42(7):2693-2696.
103	中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤相关贫血诊治专家共识(2023版)[J].中华肿瘤杂志,2023,45(12):1032-1040.
104	中国抗癌协会肿瘤支持治疗专业委员会, 中国抗癌协会肿瘤临床化疗专业委员会.肿瘤化疗导致的中性粒细胞减少诊治专家共识(2019 版)[J].中国肿瘤临床,2019,46(23):876-882.
105	中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤药物相关血小板减少诊疗专家共识(2023 版)[J].中华医学杂志,2023,103(33):2579-2590.
106	Letavernier E, Legendre C.mToR inhibitors-induced proteinuria:mechanisms, significance, and management[J].Transplant Rev(Orlando),2008,22(2):125-130.
107	Bruschi M, Granata S, Candiano G, et al.Proteomic changes induced by the immunosuppressant everolimus in human podocytes[J].Int J Mol Sci,2024,25(13):7336.
108	Arnau A, Ruiz JC,Rodrigo E,et al.Is proteinuria reversible,after withdrawal of mammalian target of rapamycin inhibitors?[ J].Transplant Proc,2011,43(6):2194-2195.
109	Fairbanks KD, Eustace JA, Fine D, et al.Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus[J].Liver Transpl, 2003, 9(10): 1079-1085.
110	Morcos A, Nair S, Keane MP, et al.Interstitial pneumonitis is a frequent complication in liver transplant recipients treated with sirolimus[J].Ir J Med Sci,2012,181(2):231-235.
111	陈方, 陶兴茹, 段彦彦.西罗莫司相关性间质性肺炎的临床特点分析[J].河南医学研究,2023,32(10):1782-1786.
112	Morath C, Schwenger V, Ksoll-Rudek D, et al.Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors[J].Transplant Proc,2007,39(1):99-102.
113	Garrean S, Massad MG, Tshibaka M, et al.Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients[J].Clin Transplant,2005,19(5):698-703.
114	中国器官移植发展基金会器官移植受者健康管理专家委员会,中国医师协会器官移植医师分会, 中华医学会器官移植学分会, 等.肝移植受者雷帕霉素靶蛋白抑制剂临床应用中国专家共识(2023 版)[J/CD].中华移植杂志: 电子版, 2023,17(4):193-204.
115	Ventura-Aguiar P, Campistol JM, Diekmann F.Safety of mTOR inhibitors in adult solid organ transplantation[J].Expert Opin Drug Saf,2016,15(3):303-319.
116	Cooper M, Wiseman AC, Zibari G, et al.Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials[J].Clin Transplant, 2013, 27(6): E625-E635.
117	Roine E, Bjork IT, Oyen O.Targeting risk factors for impaired wound healing and wound complications after kidney transplantation[J].Transplant Proc,2010,42(7):2542-2546.
118	Montalti R, Mimmo A, Rompianesi G, et al.Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation[J].Liver Transpl,2012,18(2):188-194.
119	Campistol JM, De Fijter JW, Flechner SM, et al.mTOR inhibitorassociated dermatologic and mucosal problems[J].Clin Transplant,2010,24(2):149-156.
120	Sanchez-Fructuoso AI, Ruiz JC, Perez-Flores I, et al.Comparative analysis of adverse events requiring suspension of mTOR inhibitors:everolimus versus sirolimus[J].Transplant Proc, 2010, 42(8):3050-3052.

证据级别	描述
1a	RCT的系统评价
1b	结果可信区间小的RCT
1c	显示“全或无效应”的任何证据
2a	队列研究的系统评价
2b	单个的队列研究(包括低质量的RCT,如失访率>20%者)
2c	基于患者结局的研究
3a	病例对照研究的系统评价
3b	单个病例对照研究
4	病例系列报告、低质量队列研究和低质量病例对照研究
5	专家意见(即无临床研究支持的仅依据基础研究或临床经验的推测)

证据级别	描述
1a	RCT的系统评价
1b	结果可信区间小的RCT
1c	显示“全或无效应”的任何证据
2a	队列研究的系统评价
2b	单个的队列研究(包括低质量的RCT,如失访率>20%者)
2c	基于患者结局的研究
3a	病例对照研究的系统评价
3b	单个病例对照研究
4	病例系列报告、低质量队列研究和低质量病例对照研究
5	专家意见(即无临床研究支持的仅依据基础研究或临床经验的推测)

[1]	Xuebing Shi, Yingdong Xie, Ni Xie, Chaoli Xu, Bin Yang, Guo Sun. Acoustic radiation force imaging for evaluating efficacy of radiotherapy in unresectable hepatocellular carcinoma patients with portal vein tumor thrombus [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(08): 778-784.
[2]	Senyan Hu, Dong Xu, Jian Fang, Dongdong Xie, Caiqing Wang. Clinical study of laparoscopic anatomic hepatectomy by laennec membrane approach with ICG fluorescence imaging [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 513-516.
[3]	Jinhong Gao, Yumei Chen, Yun Guo. Application effect analysis of psychological counseling based on King interactive reaching theory in patients undergoing laparoscopic hepatocellular carcinoma resection [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 517-520.
[4]	of Organ Transplantation of Chinese Medical Association Branch. Guideline on the clinical application of ex situ liver machine perfusion [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(06): 334-345.
[5]	Transplantation Group, Branch of Organ Transplantation of Chinese Liver, of Organ Transplant Physicians of Chinese Branch. Chinese guideline for clinical application of antithymocyte globulin in liver transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(06): 346-354.
[6]	Transplantation Group, Branch of Organ Transplantation of Chinese Liver, of Organ Transplant Physicians of Chinese Branch. Chinese clinical guideline for the diagnosis and treatment of sarcopenia in liver transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(06): 355-365.
[7]	Transplantation Group, Branch of Organ Transplantation of Chinese Liver, of Organ Transplant Physicians of Chinese Branch. Clinical application guideline for mycophenolate sodium in liver transplant recipients in China(2024 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(06): 366-373.
[8]	Ningning Hu, Yanrong Zhao, Dong Wang, Shengliang Wang, Yuan Guo. The correlation study between the expression of FMNL3 and prognosis in hepatocellular carcinoma liver transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(05): 283-288.
[9]	of Organ Transplant of China Medical Association Branch, of Organ Transplant Physicians of Chinese Medical Doctor Association Branch. Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after liver transplantation (2024 edition) [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 1-12.
[10]	Hanzhi Xu, Xun Qiu, Kai Wang, Xiao Xu. Study of defatting strategy for steatotic donor livers [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 18-24.
[11]	. Clinical status of laparoscopic living donor liver resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 30-35.
[12]	Binsheng Fu, Xiao Feng, Qing Yang, Kaining Zeng, Jia Yao, Hui Tang, Jianrong Liu, Xuxia Wei, Huimin Yi, Shuhong Yi, Guihua Chen, Yang Yang. Application of donor liver with steatosis in adult split liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 789-794.
[13]	of Organ Transplantation of Chinese Medical Association Branch. Chinese practice guidelines for diagnosis and treatment of ischemic-type biliary lesion after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 739-748.
[14]	Zhihong Wei, Jianyong Liu, Xiaoya Wu, Fang Yang, Lizhi Lyu, Yi Jiang, Qiucheng Cai. Diagnosis and treatment of acute graft-versus-host disease after liver transplantation （report of four cases） [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 846-851.
[15]	Ziyang Wang, Hongbin Wang, Xiaojing Liu. Progress in research of serum markers for diagnosis of alpha-fetoprotein negative hepatocellular carcinoma [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(07): 677-681.

Please choose a citation manager

Content to export